Verve Therapeutics, based in Boston, focuses on gene editing for cardiovascular diseases, employing 255 staff and going public on June 17, 2021. Its lead programs, VERVE-101, VERVE-102, and VERVE-201, target LDL-C-related genes.
Verve Therapeutics (VERV) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Verve Therapeutics's actual EPS was -$0.58, beating the estimate of -$0.71 per share, resulting in a 18.30% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
